NanoInk Imaging is pleased to announce that it has been awarded a two-year Innovation Research Fellowship Program (IRFP) grant from the New Jersey Economic Development Authority (NJEDA). This award provides critical support for early-stage technology companies and recognizes NanoInk’s potential to advance novel short-wave infrared (SWIR) imaging solutions for drug discovery and oncology research.

The IRFP grant will support the addition of highly trained scientific talent to NanoInk’s New Jersey operations, enabling accelerated development and optimization of the company’s nanocore and contrast agent technologies. By strengthening its R&D capacity, NanoInk is taking important steps toward commercialization and positioning itself to meet the growing need for advanced imaging platforms in preclinical drug development.

This award follows NanoInk’s earlier Catalyst Research & Development Grant from the New Jersey Commission on Science, Innovation and Technology (CSIT), which is supporting the establishment of nanocore synthesis capabilities in the company’s New Jersey laboratories. Together, these programs are providing a strong foundation for NanoInk’s commercialization efforts.